Sexual Reassignment Fails to Prevent Kennedy's Disease.
暂无分享,去创建一个
K. Fischbeck | D. Bakar | Nisha M. Badders | Laura C. Bott | C. Grunseich | J. Shrader | A. Burke | G. Joe | A. Schindler | A. Kokkinis | G. Harmison | T. Lanman | J. Taylor
[1] J. Andreasen,et al. Work Status and Return to the Workforce after Coronary Artery Bypass Grafting and/or Heart Valve Surgery: A One-Year-Follow Up Study , 2014, Rehabilitation research and practice.
[2] K. Fischbeck,et al. Assessing Function and Endurance in Adults with Spinal and Bulbar Muscular Atrophy: Validity of the Adult Myopathy Assessment Tool , 2014, Rehabilitation research and practice.
[3] S. Sundar,et al. Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate , 2012, BMJ Case Reports.
[4] Rebecca B. Smith,et al. Native Functions of the Androgen Receptor Are Essential to Pathogenesis in a Drosophila Model of Spinobulbar Muscular Atrophy , 2010, Neuron.
[5] K. Fischbeck,et al. Clinical features of spinal and bulbar muscular atrophy , 2009, Brain : a journal of neurology.
[6] G. Sobue,et al. Testosterone Reduction Prevents Phenotypic Expression in a Transgenic Mouse Model of Spinal and Bulbar Muscular Atrophy , 2002, Neuron.
[7] F. Orio,et al. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects , 2000, Molecular and Cellular Endocrinology.
[8] M. Rogers,et al. Spironolactone Metabolism: Steady‐State Serum Levels of the Sulfur‐Containing Metabolites , 1989, Journal of clinical pharmacology.
[9] J. Ménard,et al. Antiandrogenic effect of spirolactones: mechanism of action. , 1975, Endocrinology.
[10] K. Fischbeck,et al. Spinal and bulbar muscular atrophy: pathogenesis and clinical management. , 2014, Oral diseases.
[11] A. Karim,et al. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. , 1978, Drug metabolism reviews.